1336P - Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary heredofamiliar cancer unit implementation

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer
Cancer Aetiology, Epidemiology, Prevention
Familial Cancer
Presenter Miriam Lobo
Citation Annals of Oncology (2016) 27 (6): 462-468. 10.1093/annonc/mdw385
Authors M. Lobo1, S. Lopez-Tarruella2, S. Luque3, S. Lizarraga3, P. Rincon3, A. Hernandez3, E. Mendizabal3, O. Bueno4, M. Cebollero5, S. Perez Ramirez2, Y. Jerez2, M.I. Palomero Plaza2, R. Gonzalez del Val2, G. Garcia2, I. Echavarria Diaz-Guardamino2, A. Calin6, J.A. Blanco6, C. Flores Sanchez2, M. Martin2, I. Marquez-Rodas2
  • 1Medical Oncology, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 2Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 3Gynaecology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 4Radiology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 5Pathology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 6Radiation Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES

Abstract

Background

Identifying Breast Cancer (BC) patients with genetic risk reduces the mortality for BC and the prevention of second tumors. In 2010, we implemented a multidisciplinar Heredofamilial Cancer Unit (HFCU). We hypothesized that the creation of this HFCU improved the referral and proper preventive management of patients with BC and genetic risk.

Methods

We retrospectively compared family history record (FHR), referral of patients with high risk to genetic counseling (GC), detection and management of BRCA 1/2 mutated (+) patients, of BC patients diagnosed and treated in our institution before (July 2007-June 2010, first period) and after the HFCU creation (July 2010-June 2013, second period). Main characteristics of BRCA 1/2+ patients were also analyzed.

Results

893 patients from the first period and 902 in the second met inclusion criteria. Mean age at diagnosis was similar in both groups (57.6 vs 57.8y, p NS). 142 patients (15.9%) vs 70 (7.8%) were not analyzable because a lack of complete information to establish the genetic risk (p 

Conclusions

There is a clear improvement in FHR, referral and preventive surgeries in BC patients with genetic risk after the implementation of the HFCU. TNBC predominates in BRCA1+ while luminal in BRCA2 +.

Clinical trial identification

Legal entity responsible for the study

Hospital General Universitario Gregorio Marañon

Funding

Hospital General Universitario Gregorio Marañon

Disclosure

All authors have declared no conflicts of interest.